Isosexual precocious pseudopuberty during mitotane treatment in a child with adrenocortical carcinoma: A case report
Background: Mitotane is employed as adjuvant therapy in managing adrenocortical carcinoma in pediatric patients. While various adverse effects, such as estrogen-like manifestations, are well-documented in adults, there is limited knowledge regarding pediatric-specific toxicity. This report details a...
Saved in:
Main Authors: | Maria Riedmeier (Author), Sonir Antonini (Author), Clemens Benoit (Author), Cheri L. Deal (Author), Fassnacht Martin (Author), Bonald C. Figueiredo (Author), Elmas Nazli Gonc (Author), Christoph Härtel (Author), Jan Idkowiak (Author), Max Kurlbaum (Author), Ronald de Krijger (Author), Raul C. Ribeiro (Author), Jaydira del Rivero (Author), Paul-Gerhardt Schlegel (Author), Lester D.R. Thompson (Author), Bilgehan Yalcin (Author), Verena Wiegering (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2024-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Feminizing Adrenocortical Tumors as a Rare Etiology of Isosexual/Contrasexual Pseudopuberty
by: Doğuş Vurallı, et al.
Published: (2022) -
Effects of o,p'-DDE, a Mitotane Metabolite, in an Adrenocortical Carcinoma Cell Line
by: Camila Bach, et al.
Published: (2022) -
Low-dose mitotane-induced neurological and endocrinological complication in a 5-year-old girl with adrenocortical carcinoma
by: You Joung Heo, et al.
Published: (2022) -
Population Pharmacokinetics Modelling and Simulation of Mitotane in Patients with Adrenocortical Carcinoma: An Individualized Dose Regimen to Target All Patients at Three Months?
by: Yoann Cazaubon, et al.
Published: (2019) -
Mitotane Nanocarriers for the Treatment of Adrenocortical Carcinoma: Evaluation of Albumin-Stabilized Nanoparticles and Liposomes in a Preclinical In Vitro Study with 3D Spheroids
by: Carolin Langer, et al.
Published: (2022)